{"id":240959,"title":"Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults, CCDR 51(2/3) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-19","captureTimestamp":"2025-04-19T04:50:49.828000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/cost-effectiveness-21-valent-pneumococcal-conjugate-vaccine-adults.html?wbdisable=true","snippet":"Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults, CCDR 51(2/3) - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement du Canada Search Search Canada.ca Search Menu Main Menu Jobs and the workplace…","rawSnapshotUrl":"/api/snapshots/raw/240959","browseUrl":"https://replay.healtharchive.ca/job-1/20250419045049/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2025-51/issue-2-3-february-march-2025/cost-effectiveness-21-valent-pneumococcal-conjugate-vaccine-adults.html?wbdisable=true#ha_snapshot=240959","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}